Physician profile
Michelle Chen
NPI 1245639350
$4,509.05
in general payments reported to CMS, 2019-2025
14 companies · $716 in 2025
The $716 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $17.24 · 2021: $941 · 2022: $576 · 2023: $884 · 2024: $755 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,325.18 | 2022-2025 | Infuse, Xiidra, Miebo |
| Alcon Vision LLC | $993.35 | 2021-2025 | Total30, Precision 1, Dailies |
| Glaukos Corporation | $344.74 | 2024-2025 | Photrexa Viscous and Photrexa |
| Lensar, INC. | $309.39 | 2023 | Lensar Laser System |
| Coopervision INC. | $302.82 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $242.05 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $235.69 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $230.34 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $139.95 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $126.75 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $121.81 | 2022 | |
| Novartis Pharmaceuticals Corporation | $103.67 | 2021-2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $16.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.